Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMP 203: avutometinib + sotorasib in KRAS G12C non-small cell lung cancer
2023-505107-24-00Phase 2Authorised
- Sponsor
- Verastem Oncology
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of sotorasib and avutometinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Verastem Oncology. Primary endpoints: Dose-limiting toxicities and safety in Part A and Confirmed objective response rate in Part B. Planned start Nov 2023; status: authorised.
02
Drugs
sotorasibavutometinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-505107-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505107-24-00.